SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Realignment of Bond Repayments

5 Nov 2018 07:00

RNS Number : 2667G
Collagen Solutions PLC
05 November 2018
 

5 November 2018

 

Collagen Solutions plc

("Collagen Solutions", the "Company" or the "Group")

 

Realignment of Bond Repayments to enable further growth to be achieved

Delivering on our Growth Strategy

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that it has entered into a deed of variation to its existing Bond Subscription Agreement with Norgine Ventures. This variation provides for a 6month principal repayment holiday. While there is no current year requirement for this variation, it will provide management with greater flexibility to exploit growth opportunities for future years.

 

Consistent with the Company's ability to conservatively manage its cash balances whilst looking to exploit growth opportunities for the benefit of shareholders the Company has agreed an amendment to the timing of principal repayments on Tranche A and Tranche B Bonds issued to Norgine Ventures under the 2017 Bond Subscription Agreement. The variation gives a principal repayment holiday of six months from 31st October 2018 to 31st March 2019 with the principal repayments being instead made via a balloon payment at the redemption of the Bonds on 30 September 2020 for Tranche A and 31 January 2021 for Tranche B. Prior to this agreement, the Company remained in compliance with all payment schedules and had repaid a total of £0.42million in principal against the total £3 million drawn.

 

Commenting on outlook, Hilary Spence, CFO says: "We have seen a return to growth in the first six months of the financial year and we remain on track to meet our financial performance objectives in line with market expectations. The management team has continued to generate a large number of business leads, some of which may require incremental upfront investment on initiation. Whilst there is no current financial year requirement, with one eye on exploiting opportunities for future financial years this variation provides management greater flexibility to deliver on these leads and on other growth opportunities that will contribute to future performance."

 

 

Enquiries:

Collagen Solutions Plc

 

Jamal Rushdy, CEO 

Via Walbrook

Hilary Spence, CFO

 

 

 

Cenkos Securities Plc (Nominated Adviser and Broker)

 

Steve Cox (Corporate Finance)

Tel: 0207 397 8900

Stephen Keys

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

Helen Cresswell

Mob: 07841 917 679

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBBBDBISGBGIS
Date   Source Headline
29th Apr 20208:28 amRNSForm 8.5 (EPT/NON-RI)
28th Apr 20204:25 pmRNSForm 8.3 - Collagen Solutions plc
27th Apr 20204:22 pmRNSForm 8 (OPD) - Collagen Solutions plc
27th Apr 20202:58 pmRNSForm 8.3 - Collagen Solutions plc
27th Apr 202011:05 amRNSForm 8.3 - Collagen Solutions plc
24th Apr 20202:51 pmRNSForm 8.3 - Collagen Solutions Plc
24th Apr 20202:45 pmRNSForm 8.3
24th Apr 202012:21 pmRNSForm 8.3 - Collagen Solutions Plc
24th Apr 20209:40 amRNSForm 8.5 (EPT/NON-RI)
24th Apr 20207:00 amRNSDirector/PDMR Shareholding
23rd Apr 202012:10 pmGNWForm 8.3 - Collagen Solutions Plc
23rd Apr 20207:00 amRNSTrading update
22nd Apr 20201:30 pmRNSForm 8.3 - Collagen Solutions plc
22nd Apr 20209:27 amRNSForm 8.5 (EPT/NON-RI)
21st Apr 20209:31 amRNSForm 8.5 (EPT/NON-RI)
20th Apr 20208:21 amRNSForm 8.5 (EPT/NON-RI)
17th Apr 20202:33 pmRNSForm 8.3 - Collagen Solutions plc
17th Apr 202012:35 pmRNSForm 8.3 - Collagen Solutions plc
17th Apr 20208:35 amRNSForm 8.5 (EPT/NON-RI)
16th Apr 20207:00 amRNSStrategic Review and Formal Sale Process
18th Mar 20207:00 amRNSTrading update
3rd Dec 20197:00 amRNSHalf-year Report
19th Nov 20197:00 amRNSInvestor results presentation
13th Nov 20197:00 amRNSDirectorate Change
22nd Oct 20197:00 amRNSTrading Update & Notice of Results
3rd Oct 20197:00 amRNSDirector/PDMR Shareholding
29th Aug 20197:00 amRNSInvestor presentation
28th Aug 201911:29 amRNSResult of AGM
28th Aug 20197:00 amRNSAGM Statement
8th Aug 201910:53 amRNSDirector/PDMR Shareholding
24th Jul 20197:00 amRNSPosting of Annual Report and Notice of AGM
11th Jul 20197:00 amRNSDirector/PDMR Shareholding
9th Jul 201912:18 pmRNSHolding(s) in Company
9th Jul 20197:00 amRNSFinal Results
9th Jul 20197:00 amRNSDirectorate Change
13th Jun 20192:22 pmRNSNotice of Results
10th Jun 20195:13 pmRNSHolding(s) in Company
10th Jun 20195:09 pmRNSHolding(s) in Company
7th Jun 20199:38 amRNSHolding(s) in Company
6th Jun 20192:27 pmRNSHolding(s) in Company
6th Jun 201912:35 pmRNSHolding(s) in Company
6th Jun 20199:52 amRNSDirector/PDMR Shareholding
6th Jun 20197:00 amRNSAppointment of Non-Executive Director
5th Jun 201911:50 amRNSResult of General Meeting and Open Offer
23rd May 20197:00 amRNSInvestor presentation
20th May 20197:00 amRNSStrategic Investment, Placing and Open Offer
9th Apr 20198:08 amEQSCollagen Solutions's losses narrow on improved top line performance
9th Apr 20197:00 amRNSTrading Update
21st Mar 201911:36 amRNSHolding(s) in Company
21st Feb 20192:49 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.